Comanche secures $75M to test preeclampsia siRNA in PhII, adds Scott Gottlieb to board

Comanche Biopharma, an siRNA biotech created by veterans of The Medicines Company, has reeled in a $75 million Series B to test its drug candidate for preeclampsia, a pregnancy complication that impacts millions of women each year.

The Concord, MA-based biotech also said former FDA Commissioner Scott Gottlieb has joined its board in conjunction with announcing the oversubscribed round from New Enterprise Associates (NEA), Atlas Venture, GV, F-Prime Capital, Lilly Asia Ventures and Longview Healthcare Ventures. Gottlieb, a partner at NEA, will be joined on the board by Atlas partner David Grayzel, the company said Wednesday.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。